Category Specific RSS

Categories: News

ANZ Retail Entitlement Offer – What are your options?

If you’re an ANZ shareholder you may be wondering about the recent entitlement offer and what it means for you.

ANZ is essentially issuing new shares at $18.90 per share as a way of funding their acquisition of Suncorp’s banking division.

If you were an eligible ANZ shareholder, holding ANZ shares at 7:00 PM on the 21st of July 2022, you will receive 1 entitlement to buy an ANZ share at $18.90 for every 15 existing ANZ shares you hold.

Given that ANZ is currently trading above $18.90, these entitlements currently have intrinsic value.

If you have received these entitlements, you have a few options:

Option 1: You can take up the entitlements. To do so, head to: https://retailentitlementoffer.anz.com/offer/ and follow the prompts. You have up until 5:00 PM on 15 August 2022 to take up this option.

Option 2: You can sell your entitlements on the ASX. These entitlements are trading under the code ‘ANZR’ and they will trade up until 8 August 2022. The value of ANZR should be the intrinsic value of the entitlement (ANZ is $22.50 per share at the time of writing less the entitlement price of $18.90 means ANZR should be trading at $3.60). You should contact your broker should you wish to do this.

Option 3: Do nothing. In this case your entitlements will be sold through the retail shortfall bookbuild process, which will occur on 18 August 2022. Although you will likely get close to the intrinsic value of the entitlement at this date, there is NO GUARANTEE you will receive any value for the entitlements sold through the shortfall bookbuild. Any premium received during this process will be paid to you on or about 9 September 2022.

What option you choose may be influenced by tax or funding considerations.

Below is an indicative timetable of the relevant dates for the offer:

For any questions about your trading and investing, call (03) 8080 5788 or visit www.traderscircle.com.au.

Sam Green

Sam Green is the Portfolio Manager at Emerald Financial, whilst also being an Equities and Derivatives expert for his clients at TradersCircle.

Recent Posts

Biotron Expands into Anaesthetics with Sedarex Acquisition and $2.5m Raise

Biotech company Biotron Limited (ASX:BIT) has announced a bold step into the anaesthetics sector, acquiring…

2 days ago

DroneShield Boosts Defence Capability with $13 Million Adelaide R&D Investment

DroneShield (ASX:DRO) is expanding its Australian footprint with a $13 million investment to establish a…

2 weeks ago

Stakk Secures T-Mobile Contract to Power Super App Expansion

Australian fintech Stakk (ASX:SKK) has signed a three-year agreement with U.S. telecommunications giant T-Mobile USA,…

3 weeks ago

Medibank Backs Emyria with Landmark Depression Care Deal

Australia’s mental health burden is growing – and one of the toughest challenges is treatment-resistant…

4 weeks ago

NoviqTech Launches Quantum Intelligence Products, Opening Path to Enterprise-Grade Quantum AI

NoviqTech Limited (ASX:NVQ) has taken a decisive step into the quantum computing market, unveiling the…

4 weeks ago

BRE Wins Final Permit to Advance Rare Earth Pilot Plant in Brazil

Brazilian Rare Earths Limited (ASX:BRE) has cleared its last regulatory hurdle to begin pilot operations…

1 month ago